Mar 25, 2025
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024
Mar 23, 2025
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
Feb 28, 2025
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
Feb 25, 2025
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025
Dec 03, 2024
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Nov 27, 2024
Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy
Aug 27, 2024
Everest Medicines Announces Interim Results for First Half of 2024
Aug 05, 2024
Everest Medicines to Announce 2024 Interim Results on August 28, 2024
Mar 19, 2024
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
Mar 11, 2024
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
Mar 10, 2024
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
Mar 05, 2024
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
Feb 26, 2024
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Feb 21, 2024
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
Feb 20, 2024
Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine
Feb 18, 2024
Everest Medicines Announces Termination of Collaboration Agreements with Providence
Jan 21, 2024
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
Feb 17, 2021
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
Jan 18, 2021
Everest Medicines Announces Amended Agreement with Spero Therapeutics
Jan 06, 2021
Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer